 |
|
| EDINBURGH: NOVEMBER 2011 | |
NuCana BioMed secures $10.4 million Series A Financing to accelerate it's ProTide Anti-Cancer Drugs into Clinical Development. |
|
| Link to further details | |
 |
|
| INTERNATIONAL: NOVEMBER 2011 | |
"NuCana BioMed Gets $10.5M for ProTide Cancer Drugs" |
|
| Link to further details | |
 |
|
| SCOTLAND: NOVEMBER 2011 | |
"Life Science specialists £6.7m for new venture" |
|
| Link to further details | |
 |
|
| WALES: NOVEMBER 2011 | |
"Welsh scientists could prevent cancer cells becoming resistant to drugs". |
|
| Link to further details | |
|
|
| EDINBURGH: FEBRUARY 2011 | |
NuCana BioMed announced it had completed a further equity financing that will enable NuCana's first product to enter clinical development. |
|
| Link to further details | |
 |
|
| EDINBURGH: FEBRUARY 2011 | |
Hugh Griffth to be the Keynote Speaker at the prestigious Scottish Enterprise Life Sciences Annual Dinner on 3rd February 2011. |
|
| Link to further details | |
 |
|
| CARDIFF: JANUARY 2011 | |
Chris Wood to present at Cardiff University EPSRC/PRESIDENTS ENTREPRENEURSHIP DAY on "Discovering New Medicines & Making Money". |
|
|
|
| EDINBURGH: DECEMBER 2010 | |
NuCana BioMed announces the appointment of Martin Mellish as Non Executive Director to the Board of Directors. |
|
 |
|
| EDINBURGH: JUNE 2010 | |
Hugh Griffith guest speaker at BIA & Ernst & Young 'Beyond Borders' Seminar. |
|
| Link to further details | |
 |
|
| EDINBURGH: MAY 2010 | |
Hugh Griffith provides vision for challenges facing Biotechnology in the foreword to Marks & Clerk Life Sciences Report 2010. |
|
| Link to further details | |
 |
CARDIFF: APRIL 2010 |
Christopher Wood to present at Wales Cancer Conference in Cardiff, 14th - 15th April 2010. |
|
| Link to further details | |
 |
|
| EDINBURGH: FEBRUARY 2010 | |
Hugh Griffith to present at BIA Scotland BioLeadership Forum and Dinner, 4th February 2010. |
|
| Link to further details | |
|
EDINBURGH: 18 December 2009 |
| NuCana BioMed Completes Financing to Expand Anti-Cancer Drug Development Programme | |
NuCana BioMed Ltd ("NuCana") today announced it had completed a further equity financing that will allow the company to rapidly expand its drug development programme of new anti-cancer agents. |
|
| Links to full story | |
 |
EDINBURGH: 18 December 2009 |
| Alida Capital International Completes Financing into NuCana BioMed | |
| Alida Capital International Ltd ("Alida") today announced it had completed an equity financing into Edinburgh based biopharmaceutical company NuCana BioMed ("NuCana"). The Scottish Enterprise Scottish Co-Investment Fund participated in the round. | |
| Links to full story | |
 |
CARDIFF: 18 November 2009 |
| Morvus Technology and NuCana BioMed sign exclusive world-wide licence to develop ProTide Technology in Cancer | |
| Morvus Technology Ltd ("Morvus") and NuCana BioMed Ltd ("NuCana") today announce that an agreement has been signed by which Morvus has granted to NuCana an exclusive, world-wide, licence with rights to develop its ProTide technology for the enhancement of nucleoside analogues ("nucleosides"). | |
| Links to full story | |